Source:http://linkedlifedata.com/resource/pubmed/id/17580000
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2007-6-20
|
pubmed:abstractText |
The CCAAT/enhancer binding protein alpha (C/EBPalpha or CEBPA) is the founding member of a family of related leucine zipper transcription factors that play important roles in myeloid differentiation. Targeted inactivation of C/EBPalpha in mice demonstrates its importance in the proper development and function of liver, adipose tissue, lung and haematopoietic tissues. C/EBPalpha is highly expressed in these differentiated tissues where it controls differentiation-dependent gene expression and inhibits cell proliferation. Learning more about the precise molecular functions of the C/EBPalpha protein and how these are affected by leukaemogenic mutations should lead to an improved understanding of the cellular functions that are disrupted in patients with AML. Decreased expression of C/EBPalpha but not C/EBPalpha mutation has been shown in patients with granulocytic leukaemias that are associated with translocations t(8;21), inv (16) or t(15;17). Derived fusion proteins repress C/EBPalpha expression. Differentiation therapy of some AML types is based on restoring C/EBPalpha function. However, apparently normal C/EBPalpha is overexpressed in BCP-ALL harbouring the translocation t(14; 19)(q32; q13). C/EBPalpha may exhibit oncogenic as well as tumour suppressor properties in human leukaemogenesis. C/EBPalpha mutations were not found in non-haematopoietic cancers. DNA hypermethylation of the upstream C/EBPalpha promoter region is responsible for very low C/EBPalpha expression in human lung and endometrial cancer. C/EBPalpha expression may be a biomarker for early detection of these cancers and DNA-modifying drugs such as demethylating agents and/or histone deacetylase inhibitors could be used in the treatment of these malignancies.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CCAAT-Enhancer-Binding Protein-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Growth Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Proteins
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0015-5500
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
53
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
97-108
|
pubmed:meshHeading |
pubmed-meshheading:17580000-Animals,
pubmed-meshheading:17580000-CCAAT-Enhancer-Binding Protein-alpha,
pubmed-meshheading:17580000-Growth Inhibitors,
pubmed-meshheading:17580000-Hematopoiesis,
pubmed-meshheading:17580000-Humans,
pubmed-meshheading:17580000-Leukemia,
pubmed-meshheading:17580000-Oncogene Proteins,
pubmed-meshheading:17580000-Tumor Suppressor Proteins
|
pubmed:year |
2007
|
pubmed:articleTitle |
Growth-inhibiting activity of transcription factor C/EBPalpha, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias.
|
pubmed:affiliation |
Institute of Haematology and Blood Transfusion, Prague, Czech Republic. Ota.Fuchs@uhkt.cz
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|